NICOLE MAKRAKIS: Open Payments
NPI 1033899794 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$842 in 19 payments from 5 companies in 2025. Trend: 2023 $30 · 2024 $182 · 2025 $842
Food & beverage: $842
| Company | Payments | Amount |
|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 9 | $508 |
| Gilead Sciences, Inc. | 1 | $147 |
| Madrigal Pharmaceuticals | 4 | $94 |
| Ipsen Biopharmaceuticals, Inc | 4 | $79 |
| Novo Nordisk Inc | 1 | $15 |
Products named: XIFAXAN, REZDIFFRA, IQIRVO, Wegovy.
Industry payments across TX — which companies pay providers there.
